Medtronic showcases over 100 innovative products and solutions at 8th CIIE

On November 5, 2025, the 8th China International Import Expo (CIIE) officially commenced. As a regular participant with a perfect attendance record, Medtronic returned under the theme "Innovating Healthcare Together," showcasing over 100 innovative products and solutions. Both the booth area and number of exhibits reached record highs, comprehensively displaying Medtronic's cutting-edge innovations in medical technology, particularly in the field of intelligent healthcare. The company demonstrated its deepened local layout across the "R&D chain," "incubation chain," and "supply chain," reaffirming its steadfast commitment to advancing the high-quality development of healthcare in China.

Building on its tradition of annual new product launches, Medtronic focused this year on the deep integration of artificial intelligence and healthcare, introducing six debut exhibits. These showcases demonstrated the practical clinical application of digital-intelligent healthcare technologies and offered a redefinition of future diagnosis and treatment pathways and experiences.

The Asia-Pacific debut featured Medtronic's Inceptiv*, the world's first closed-loop rechargeable spinal cord stimulation system, which was previously named one of TIME Magazine's 2024 Best Inventions. This system can "listen to the body's signals," detecting changes in spinal bio-signals during different movements and automatically adjusting stimulation in real-time. This ensures chronic pain patients receive a more consistent, stable, and sustained therapeutic experience.

The five China-debut exhibits included the Affera™ Electrophysiology 3D Navigation and Pulsed Field Ablation System* and the matching Sphere-9™ Pulsed Field Dual-Energy and High-Density Mapping All-in-One Catheter*. This combination enables physicians to complete a full workflow—from identifying cardiac issues and precisely locating lesions, to delivering treatment and confirming outcomes—thereby enhancing procedural efficiency and operational accuracy. 

The CathWorks FFRangio® System, empowered by digital technology, transforms the traditional invasive FFR (Fractional Flow Reserve) measurement into a more convenient and rapid functional assessment method, potentially advancing coronary physiology from a "selective tool" to "routine clinical practice."

The Avalus Ultra™ Artificial Heart Valve, which highly simulates the function of the native human valve, offers an innovative solution for tens of millions of Chinese patients with valvular heart disease.

Lastly, the OmniaSecure™ Implantable Defibrillator Lead*, with a diameter of only about 1.6 mm, provides a more durable solution for patients at high risk of Sudden Cardiac Arrest (SCA).

Thanks to the strong spillover effect of the CIIE, more than 30 of Medtronic's star exhibits have been successfully translated into clinical practice, benefiting Chinese patients. For instance, the EV-ICD (Extravascular Implantable Cardioverter-Defibrillator) for the treatment of sudden cardiac death, driven by the "Greater Bay Area (GBA) Access Policy" for drugs and medical devices in the Guangdong-Hong Kong-Macao Greater Bay Area, completed its first implants in China in September this year. Meanwhile, the Penditure Left Atrial Appendage Closure System*, which debuted last year, is also expected to receive approval for use under the same policy following its exhibition.

Medtronic's strategic product in the brain-computer interface field, the rechargeable and perceptive closed-loop brain pacemaker Percept™ RC, which was first exhibited last year, is poised to enter clinical application in China. The Symplicity RDN (Renal Denervation) therapy for resistant hypertension, after being showcased at the CIIE, completed its "first procedure in China" the following year under the Boao Lecheng Pilot Zone's pioneering policy. To date, over 100 clinical procedures have been completed in China, truly transforming this "CIIE exhibit" into a "clinical commodity" that safeguards patient health.

Furthermore, several other innovative products are benefiting broader patient populations in China, aided by the CIIE's spillover effect. These include the Signia Smart Anastomosis Platform for surgery, the INVOS 7100 cerebral and regional oximetry monitor that provides "immediate warning" of perioperative low cerebral oxygen events, the StealthStation Flex ENT electromagnetic navigation system dedicated to ENT procedures, the Pipeline Flex Embolization Device for treating intracranial aneurysms, and the Barrx endoscopic radiofrequency ablation system, which offers uniform, depth-controlled ablation for treating gastrointestinal mucosal lesions.

Beyond accelerating the introduction of global innovations, Medtronic has also successfully transitioned from "exhibitor" to "investor." Through deep commitment to local R&D and manufacturing, Medtronic has established several core bases in China. A notable example is the NIM-ECLIPSE intraoperative neural monitoring system, developed at the Medtronic Kanghui (Changzhou) Technology Park. It received approval from Japan's PMDA in June and officially entered the Japanese market, with its first clinical case completed in September, serving as a model of "Made in China for the World." Additionally, the Medtronic Kangdi Surgical Integration Base and the Medtronic Lingang Medical Technology Industrial Base are key components of Medtronic's local strategic footprint in China.

Focusing on AI + Healthcare, Medtronic's first Digital Healthcare Innovation Base in China was officially inaugurated at the Beijing International BioPark on October 25, 2025. This base is poised to become a key hub connecting Medtronic's global innovation capabilities with local ecosystem partners in China.

Concurrently, at this year's CIIE, Medtronic announced the launch of its first localized AI solution for TAVR procedures. Developed in collaboration with local physicians and AI enterprises, this solution aims to build a comprehensive diagnosis and treatment chain covering the entire patient pathway. Through this innovative model, Medtronic is committed to creating a new ecosystem for intelligent therapy, also providing a new direction for the industry in exploring the integration of AI and healthcare.